Voters in Michigan have voted to legalise the recreational use of cannabis, while those in North Dakota rejected it. In Utah and Missouri medical cannabis use was approved on the day the US turned out to vote in the midterm elections.
Michigan voters passed an initiative on recreational use with just shy of 57% approval. The initiative was considered generally permissive. Its passing will make it legal in the state for those over 21 to buy and possess 2.5oz. It also enacted a 10% excise sales tax.
...
Need help?
Contact a sales representative right now and don’t wait
“ Michigan says yes, North Dakota says no to recreational cannabis ”
Buy report request information:
“ Michigan says yes, North Dakota says no to recreational cannabis ”
Voters in Michigan have voted to legalise the recreational use of cannabis, while those in North Dakota rejected it. In Utah and Missouri medical cannabis use was approved on the day the US turned out to vote in the midterm elections.
Michigan voters passed an initiative on recreational use with just shy of 57% approval. The initiative was considered generally permissive. Its passing will make it legal in the state for those over 21 to buy and possess 2.5oz. It also enacted a 10% excise sales tax.
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Benefits of subscription plans:
Stay informed of any legal and market change in the sector that impacts your organization
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Need help?
Contact a sales representative right now and don’t wait
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.